The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Diabetes and the Risk of Developing Parkinson’s Disease in Denmark
Open accessAbstract
OBJECTIVE: Insulin contributes to normal brain function. Previous studies have suggested associations between midlife diabetes and neurodegenerative diseases, including Parkinson’s disease. Using Danish population registers, we investigated whether a history of diabetes or the use of antidiabetes drugs was associated with Parkinson’s disease. RESEARCH DESIGN AND METHODS: From the nationwide Danish Hospital Register hospital records, we identified 1,931 patients with a first-time diagnosis of Parkinson’s disease between 2001 and 2006. We randomly selected 9,651 population control subjects from the Central Population Registry and density matched them by birth year and sex. Pharmacy records comprising all antidiabetes and anti-Parkinson drug prescriptions in Denmark were available. Odds ratios (ORs) were estimated by logistic regression models. RESULTS: Having diabetes, as defined by one or more hospitalizations and/or outpatient visits for the condition, was associated with a 36% increased risk of developing Parkinson’s disease (OR 1.36 [95% CI 1.08–1.71]). Similarly, diabetes defined by the use of any antidiabetes medications was associated with a 35% increased Parkinson’s disease risk (1.35 [1.10–1.65]). When diabetes was defined as the use of oral antidiabetes medications, effect estimates were stronger in women (2.92 [1.34–6.36]), whereas when diabetes was defined as any antidiabetes drug prescription, patients with early-onset Parkinson’s disease were at highest risk (i.e., Parkinson’s disease diagnosed before the age of 60 years; 3.07 [1.65–5.70]). CONCLUSIONS: We found that a diagnosis of, or treatment received for, diabetes was significantly associated with an increased risk of developing Parkinson’s disease, especially younger-onset Parkinson’s disease. Our results suggest a common pathophysiologic pathway between the two diseases. Future studies should take age at Parkinson’s disease onset into account.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Type 2 Diabetes and the Risk of Parkinson's Disease
Hu, G., Jousilahti, P., Bidel, S., Antikainen, R., & Tuomilehto, J. (2007) · Diabetes Care · doi:10.2337/dc06-2011 · Cited by 466
Cited by
The epidemiology of Parkinson's disease: risk factors and prevention
Ascherio, A., & Schwarzschild, M. A. (2016) · The Lancet Neurology · doi:10.1016/s1474-4422(16)30230-7 · Cited by 1,825
Inflammation in Parkinson’s Disease: Mechanisms and Therapeutic Implications
Pajares, M., I. Rojo, A., Manda, G., Boscá, L., & Cuadrado, A. (2020) · Cells · doi:10.3390/cells9071687 · Cited by 779
Schalkwijk, C. G., & Stehouwer, C. D. A. (2020) · Physiological Reviews · doi:10.1152/physrev.00001.2019 · Cited by 622
Ghaisas, S., Maher, J., & Kanthasamy, A. (2016) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2015.11.012 · Cited by 521
Insulin resistance and Parkinson’s disease: A new target for disease modification?
Athauda, D., & Foltynie, T. (2016) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2016.10.001 · Cited by 328
The Therapeutic Potential of Metformin in Neurodegenerative Diseases
Rotermund, C., Machetanz, G., & Fitzgerald, J. C. (2018) · Frontiers in Endocrinology · doi:10.3389/fendo.2018.00400 · Cited by 304
Athauda, D., Gulyani, S., Karnati, H. K., Li, Y., Tweedie, D., Mustapic, M., Chawla, S., Chowdhury, K., Skene, S. S., Greig, N. H., et al. (2019) · JAMA Neurology · doi:10.1001/jamaneurol.2018.4304 · Cited by 258
Type 2 Diabetes as a Determinant of Parkinson's Disease Risk and Progression
Chohan, H., Senkevich, K., Patel, R. K., Bestwick, J. P., Jacobs, B. M., Bandres Ciga, S., Gan‐Or, Z., & Noyce, A. J. (2021) · Movement Disorders · doi:10.1002/mds.28551 · Cited by 228
Kuan, Y.-C., Huang, K.-W., Lin, C.-L., Hu, C.-J., & Kao, C.-H. (2017) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2017.06.002 · Cited by 168
Hong, C.-T., Chen, K.-Y., Wang, W., Chiu, J.-Y., Wu, D., Chao, T.-Y., Hu, C.-J., Chau, K.-Y., & Bamodu, O. (2020) · Cells · doi:10.3390/cells9030740 · Cited by 133
In utero exposure to selective serotonin reuptake inhibitors and risk for autism spectrum disorder
Gidaya, N. B., Lee, B. K., Burstyn, I., Yudell, M., Mortensen, E. L., & Newschaffer, C. J. (2014) · Journal of Autism and Developmental Disorders · doi:10.1007/s10803-014-2128-4 · Cited by 115
“2013) and these coding schemes have been employed in a variety of studies (Gislason et al. 2006; Kaae et al. 2010; Moth et al. 2008; Schernhammer et al. 2011).”
BackgroundMethodIs cardiac function impaired in premotor Parkinson's disease? A retrospective cohort study
Palma, J., Carmona‐Abellan, M., Barriobero, N., Trevino-Peinado, C., Garcia‐Lopez, M., Fernandez‐Jarne, E., & Luquin, M. R. (2013) · Movement Disorders · doi:10.1002/mds.25431 · Cited by 77
A nationwide cohort study on diabetes severity and risk of Parkinson disease
Han, K., Kim, B., Lee, S. H., & Kim, M. K. (2023) · npj Parkinson's Disease · doi:10.1038/s41531-023-00462-8 · Cited by 67
Mitochondrial Chaperones in the Brain: Safeguarding Brain Health and Metabolism?
Castro, J. P., Wardelmann, K., Grune, T., & Kleinridders, A. (2018) · Frontiers in Endocrinology · doi:10.3389/fendo.2018.00196 · Cited by 53
Dopamine-mediated autocrine inhibition of insulin secretion
Ferrero, E., Masini, M., Carli, M., Moscato, S., Beffy, P., Vaglini, F., Mattii, L., Corti, A., Scarselli, M., Novelli, M., et al. (2024) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2024.112294 · Cited by 4
“…to induce an aggravation of symptoms in Parkinson ’ s disease patients (Sandyk, 1993a) and epidemiological studies indicate that diabetes can be considered as a risk factor for Parkinson ’ s disease (Hu et al., 2007; Cereda et al., 2012; Sandyk, 1993b; Schernhammer et al., 2011; Sun et al., 2012).”
Metadata
- Authors
- Schernhammer, E., Hansen, J., Rugbjerg, K., Wermuth, L., & Ritz, B.
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2011-04-20
- Volume
- 34
- Issue
- 5
- Pages
- 1102-1108
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- OpenAlex
- W2166517927
- Cited by
- 198
- References
- 1
- FWCI
- 6.59
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.